Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect:: a retrospective analysis

被引:24
|
作者
Meinardi, JR
Middeldorp, S
de Kam, PJ
Koopman, AMW
van Pampus, ECM
Hamulyák, K
Prins, MH
Büller, HR
van der Meer, J
机构
[1] Univ Hosp, Div Haemostasis Thrombosis & Rheol, NL-9713 GZ Groningen, Netherlands
[2] Univ Hosp, Trial Coordinat Ctr, Groningen, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Ctr Haemostasis Thrombosis Atherosclerosis & Infl, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Hosp, Dept Haematol, Maastricht, Netherlands
关键词
thromboembolism; blood coagulation disorders; activated protein C resistance; factor V;
D O I
10.1097/00001721-200112000-00014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Factor V Leiden is the most common genetic defect associated with venous thromboembolism. Its clinical expression is limited and shows a wide intrafamilial and interfamilial variation, which might be explained by the influence of other genetic risk factors. We retrospectively studied 226 patients with factor V Leiden and documented venous thromboembolism (probands) and 400 first-degree carrier relatives to assess the contribution of concomitant genetic risk factors to the occurrence of venous thromboembolism. The prothrombin G20210A mutation was found in 8.3%, homozygosity of factor V Leiden in 7.2%, and inherited deficiencies of antithrombin, protein C or protein S in 4.7% of symptomatic carriers (probands and relatives), as compared with 6.0, 3.4 and 0.9% of asymptomatic carriers, respectively. The total follow-up time in relatives was 11049 years. Prevalences of venous thromboembolism were 10.8% in single heterozygous factor V Leiden carrier relatives, 16.0% in double-heterozygotes for factor V Leiden and the prothrombin mutation, 36.8% in homozygotes for factor V Leiden, and 40.0% in double-heterozygotes for factor V Leiden and an inherited deficiency of protein C or protein S. Annual incidences in these groups were 0.39, 0.57, 1.41, and 4.76%, respectively. Multivariate analysis showed a small, non-significant additional effect of the prothrombin mutation on the risk of venous thromboembolism in heterozygotes for factor V Leiden [adjusted hazard ratio, 1.3; 95% confidence interval (CI), 0.5-3.8]. This effect was more pronounced for homozygosity of factor V Leiden (adjusted hazard ratio, 3.9; 95% CI, 1.7-9.0) and inherited protein C or protein S deficiencies (adjusted hazard ratio, 17.5; 95% CI, 3.8-81.2). Our data provide evidence of clustering of the evaluated genetic thrombophilic defects in symptomatic factor V Leiden carriers and support the assumption that the clinical expression of factor V Leiden depends on clustering in a part of carriers. Blood Coagul Fibrinolysis 12:713-720 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:713 / 720
页数:8
相关论文
共 50 条
  • [41] Venous thromboembolism in carriers of the Factor V!Leiden mutation and in patients without known thrombophilic risk factor;: prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity
    Strandberg, Karin
    Svensson, Peter J.
    Ohlin, Ann-Kristin
    THROMBOSIS RESEARCH, 2007, 121 (02) : 145 - 151
  • [42] Duration of anticoagulation and risk of recurrent thromboembolism in carriers of factor V Leiden or prothrombin mutation
    Prandoni, P.
    Tormene, D.
    Spiezia, L.
    Pesavento, R.
    Simioni, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (12)
  • [43] Enhanced risk of venous thromboembolism in factor V Leiden carriers on oral-contraceptive use: Rationale for a limited screening for the mutation
    Schambeck, CM
    Grossmann, R
    Haubitz, I
    Scheuer, H
    Schmitt, R
    Schwab, J
    Schwender, S
    Spengler, A
    Keller, F
    THROMBOSIS AND HAEMOSTASIS, 1997, : P1260 - P1260
  • [44] Factor V HR2 haplotype: a risk factor for venous thromboembolism in individuals with absence of Factor V Leiden
    Zaher K. Otrock
    Ali T. Taher
    Wael A. Shamseddeen
    Ghazi Zaatari
    Ali Bazarbachi
    Rami A. Mahfouz
    Annals of Hematology, 2008, 87 : 1013 - 1016
  • [45] Factor V Leiden Associated Venous Thromboembolism Risk Declines With Age in the UK Biobank
    Clapham, Katharine
    Gilliland, Thomas
    Haidermota, Sara
    Koyama, Satoshi
    Natarajan, Pradeep
    CIRCULATION, 2022, 146
  • [46] Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism
    Ridker, PM
    Hennekens, CH
    Selhub, J
    Miletich, JP
    Malinow, MR
    Stampfer, MJ
    CIRCULATION, 1997, 95 (07) : 1777 - 1782
  • [47] The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study
    Heit, JA
    Sobell, JL
    Li, H
    Sommer, SS
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (02) : 305 - 311
  • [48] Recurrent venous thromboembolism is associated with Factor V Leiden mutation
    Sveinsdottir, S., V
    Saemundsson, Y.
    Isma, N.
    Gottsater, A.
    Svensson, P. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 734 - 734
  • [49] The association of factor V Leiden with various clinical patterns of venous thromboembolism-the factor V Leiden paradox
    Hirmerova, J.
    Seidlerova, J.
    Subrt, I.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2014, 107 (09) : 715 - 720
  • [50] ABO blood group and risk of venous thrombosis in heterozygous carriers of factor V leiden
    Robert, A
    Aillaud, MF
    Eschwège, V
    Randrianjohany, A
    Scarabin, Y
    Juhan-Vague, I
    THROMBOSIS AND HAEMOSTASIS, 2000, 83 (04) : 630 - 631